Trasylol (aprotinin) as an anti-tumour agent

Growth of a syngeneic adenocarcinoma in C3H mice was investigated in animals receiving twice-daily subcutaneous injections of the antiprotease Trasylol. Development of primary tumours was not influenced by Trasylol treatment and the antiprotease did not affect concomitant ant--tumour immunity as assessed by resistance to secondary footpad challenge. From histological examination of tumours and a study of GVH (graft-versus-host) activity no evidence was gained that Trasylol treatment augments the host cellular immune response.